The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
20 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $36,601,494 in first-year total cost, median $763,493.
Most frequent study sections
- Special Emphasis Panel[ZRG1 BBBP-Z (55)]20
Most frequent institutions
- BETH ISRAEL DEACONESS MEDICAL CENTER2
- UNIVERSITY OF KANSAS MEDICAL CENTER2
- UNIVERSITY OF KENTUCKY2
- COGNITION THERAPEUTICS, INC.1
- EMORY UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | US POINTER Neuroimaging Ancillary Study1R01AG062689-01 | LANDAU, SUSAN M | UNIVERSITY OF CALIFORNIA BERKELEY, CA | $11,343,101 | ZRG1 |
| 2019 | A Seamless Phase 2A-B Randomized Double Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of PQ 912 in Patients with Early Alzheimer's Disease1R01AG061146-01 | FELDMAN, HOWARD | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $5,279,327 | ZRG1 |
| 2019 | A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimerʼs Disease1RF1AG058710-01A1 | CAGGIANO, ANTHONY O | COGNITION THERAPEUTICS, INC., PA | $3,300,642 | ZRG1 |
| 2019 | Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects1R01AG061122-01 | DIDSBURY, JOHN | T3D THERAPEUTICS, INC., NC | $2,292,799 | ZRG1 |
| 2019 | A randomized, double blind, placebo-controlled study to evaluate the impact of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)1R01AG062463-01 | MOUSSA, CHARBEL | GEORGETOWN UNIVERSITY, DC | $1,417,321 | ZRG1 |
| 2019 | First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation1R01AG061898-01 | VAN ELDIK, LINDA JWATTERSON, DANIEL MARTIN | UNIVERSITY OF KENTUCKY, KY | $1,403,277 | ZRG1 |
| 2019 | Efficacy of Adapted Tai Ji Quan to Slow Cognitive Decline in Older Adults1R01AG059546-01A1 | LI, FUZHONG | OREGON RESEARCH INSTITUTE, OR | $782,329 | ZRG1 |
| 2019 | Evaluating the disease-modifying potential of a sleep intervention for Alzheimer's Disease outcomes1R01AG062673-01 | DENBURG, NATALIE L | UNIVERSITY OF IOWA, IA | $768,747 | ZRG1 |
| 2019 | Primary Prevention of Alzheimer's disease: Examining the effects of cognitive behavioral therapy on cognitive function and amyloid-beta in older adults with symptoms of insomnia1R01AG058530-01A1 | SIENGSUKON, CATHERINE F | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $763,979 | ZRG1 |
| 2019 | Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArTâHS)1R01AG061111-01 | JICHA, GREGORY ANELSON, PETER T. | UNIVERSITY OF KENTUCKY, KY | $763,006 | ZRG1 |
| 2019 | A Novel Computerized Cognitive Stress Test Designed for Clinical Trials in Early Alzheimer's: Relationship with Multimodal Imaging Biomarkers in Diverse Cultural Groups1R01AG061106-01 | LOEWENSTEIN, DAVID | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $748,976 | ZRG1 |
| 2019 | (-)-Phenserine inhibition of neuronal death in Alzheimer’s disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial1R01AG062687-01 | BALLARD, CLIVESCHNEIDER, LON S | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $725,263 | ZRG1 |
| 2019 | Validation and Mechanistic Interrogation of Metabolism Targeting for AD1R01AG060733-01A1 | SULLIVAN, DEBRA KSWERDLOW, RUSSELL H. | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $721,830 | ZRG1 |
| 2019 | Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)1R01AG062200-01 | CARMICHAEL, OWEN T.NEWTON, ROBERT LEE | LSU PENNINGTON BIOMEDICAL RESEARCH CTR, LA | $715,602 | ZRG1 |
| 2019 | Reducing Risk of Dementia through De-prescribing (R2D2)1R01AG061452-01 | CAMPBELL, NOLL L. | PURDUE UNIVERSITY, IN | $691,971 | ZRG1 |
| 2019 | Gamma Induction for Amyloid Clearance in Alzheimer’s Disease1R01AG060981-01 | SANTARNECCHI, EMILIANO | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $649,289 | ZRG1 |
| 2019 | Partnered Rhythmic Rehabilitation for Enhanced Motor-Cognition in Prodromal Alzheimer's Disease1R01AG062691-01 | HACKNEY, MADELEINE EVE | EMORY UNIVERSITY, GA | $628,597 | ZRG1 |
| 2019 | Influence of Strategy Training on Disability for Older Adults with Mild Cognitive Impairment1R01AG056351-01A1 | RODAKOWSKI, JULEEN | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $619,155 | ZRG1 |
| 2019 | Treating hyperexcitability in Alzheimer’s disease with levetiracetam to improve brain function and cognition1R01AG060987-01 | SHAFI, MOUHSIN | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $571,143 | ZRG1 |
| 2018 | A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)1R01AG061100-01 | FORESTER, BRENT PETERPETRIDES, GEORGIOS | MCLEAN HOSPITAL, MA | $2,415,140 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.